AMEX:NNVC (USA)
Business Description
Nanoviricides Inc
NAICS : 325412
SIC : 2834
1 Controls Drive, Shelton, CT, USA, 06484
Compare
Compare
Traded in other countries / regions
NV3N.Germany
•
NNVC.USA
Description
Nanoviricides Inc is a nano-biopharmaceutical company which is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through an in-licensing strategy.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 94.38 | |||||
| Equity-to-Asset | 0.99 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 31.2 | |||||
| 3-Year EPS without NRI Growth Rate | 32.6 | |||||
| 3-Year FCF Growth Rate | 32 | |||||
| 3-Year Book Growth Rate | -20.2 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 87.06 | |||||
| 9-Day RSI | 82.23 | |||||
| 14-Day RSI | 77.65 | |||||
| 6-1 Month Momentum % | -22.31 | |||||
| 12-1 Month Momentum % | -51.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 41.21 | |||||
| Quick Ratio | 41.21 | |||||
| Cash Ratio | 40.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -49.3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -29.72 | |||||
| ROA % | -29.13 | |||||
| ROIC % | -88.89 | |||||
| ROC (Joel Greenblatt) % | -92.85 | |||||
| ROCE % | -29.66 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.65 | |||||
| Price-to-Tangible-Book | 1.68 | |||||
| EV-to-EBIT | -3.04 | |||||
| EV-to-EBITDA | -3.32 | |||||
| EV-to-FCF | -3.61 | |||||
| Price-to-Net-Current-Asset-Value | 2.62 | |||||
| Price-to-Net-Cash | 2.7 | |||||
| Earnings Yield (Greenblatt) % | -32.89 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with AMEX:NNVC
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -0.74 | ||
| Beta | 0.62 | ||
| Volatility % | 69.92 | ||
| 14-Day RSI | 77.65 | ||
| 14-Day ATR ($) | 0.334753 | ||
| 20-Day SMA ($) | 2.177 | ||
| 12-1 Month Momentum % | -51.92 | ||
| 52-Week Range ($) | 1.04 - 7.86 | ||
| Shares Outstanding (Mil) | 11.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nanoviricides Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||